TY - JOUR
AU - Pearson, Lesley-Anne
AU - Green, Charlotte
AU - Lin, De
AU - Petit, Alain-Pierre
AU - Gray, David
AU - Cowling, Victoria H.
AU - Fordyce, Euan
PY - 2021
DA - March
TI - Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7 Methyltransferase Using RapidFire Mass Spectrometry
JO - SLAS Discovery
DO - https://doi.org/10.1177/24725552211000652
AB - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) represents a significant threat to human health. Despite its similarity to related coronaviruses, there are currently no specific treatments for COVID-19 infection, and therefore there is an urgent need to develop therapies for this and future coronavirus outbreaks. Formation of the cap at the 5′ end of viral RNA has been shown to help coronaviruses evade host defenses. Nonstructural protein 14 (nsp14) is responsible for N7-methylation of the cap guanosine in coronaviruses. This enzyme is highly conserved among coronaviruses and is a bifunctional protein with both N7-methyltransferase and 3′-5′ exonuclease activities that distinguish nsp14 from its human equivalent. Mutational analysis of SARS-CoV nsp14 highlighted its role in viral replication and translation efficiency of the viral genome. In this paper, we describe the characterization and development of a high-throughput assay for nsp14 utilizing RapidFire technology. The assay has been used to screen a library of 1771 Food and Drug Administration (FDA)-approved drugs. From this, we have validated nitazoxanide as a selective inhibitor of the methyltransferase activity of nsp14. Although modestly active, this compound could serve as a starting point for further optimization.
PB - SAGE Publications
UR - https://discovery.dundee.ac.uk/en/publications/77802fb3-98d9-4c6c-871d-529926aa3df1
KW - Coronavirus (COVID-19)
ER